LNA antagonists targeting the androgen receptor
View Patent ↗The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
1. An oligomer consisting of the formula:
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.
2. A conjugate comprising the oligomer of claim 1 covalently attached to at least one moiety that is not a nucleic acid or a monomer.
3. A pharmaceutical composition comprising:
the oligomer of claim 1 or a conjugate comprising said oligomer covalently attached to at least one moiety that is not a nucleic acid or a monomer; and
a pharmaceutically acceptable diluent, carrier, salt or adjuvant.
4. A method of inhibiting the expression of androgen receptor in a cell, comprising:
contacting said cell with an effective amount of an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.
5. A method of inhibiting the expression of androgen receptor in a cell, comprising contacting said cell with an effective amount of a conjugate according to claim 2 .
6. A method of inhibiting the expression of androgen receptor in a tissue of a mammal, comprising:
contacting said tissue with an effective amount of an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.
7. A method of inhibiting the expression of androgen receptor in a tissue of a mammal comprising contacting said tissue with an effective amount of a conjugate according to claim 2 .
8. A method of inhibiting the expression of an androgen receptor target gene in a cell or tissue of a mammal, comprising:
contacting said cell or tissue with an effective amount of an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.
9. A method of treating breast cancer or prostate cancer in a mammal, comprising;
administering to said mammal an effective amount of an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.
10. A method of treating a disorder in a mammal, comprising:
administering to said mammal an effective amount of an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base,
wherein said disorder is selected from the group consisting of alopecia, benign prostatic hyperplasia, spinal and muscular atrophy, Kennedy disease, and polyglutamate disease.
11. An activated oligomer comprising:
an oligomer consisting of the formula
(SEQ ID NO: 58)
5′-A s Me C s Me C s a s a s g s t s t s t s c s t s t s c s A s G s Me C-3′,
wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript “s” denotes a phosphorothioate linkage, and Me C denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base; and
at least one functional group covalently attached thereto at one or more positions independently selected from the 5′-end, the 3′ end, the 2′-OH of a ribose sugar, and the base.